ADHD medicine may be part of how you manage work, appointments, routines and everyday safety. Trying to conceive does not automatically mean dexamfetamine, lisdexamfetamine, methylphenidate or another prescribed ADHD medicine must stop. The useful next step is a preconception review of the exact medicine, dose, formulation, side effects and support it provides — not a fixed washout period copied from the internet.
Australian treatment commonly includes dexamfetamine, also called dexamphetamine, lisdexamfetamine such as Vyvanse, and methylphenidate such as Ritalin, Ritalin LA and Concerta. Most research examines pregnancy outcomes rather than ovulation, egg quality, implantation or time to pregnancy, so fertility questions need to stay separate from pregnancy-safety questions.
Do not change the dose or stop treatment on your own. If you are planning pregnancy, arrange the review before conception where possible and agree on a written plan for trying, fertility treatment and a positive pregnancy test.
Quick answers about ADHD medication and fertility
Can you take ADHD medication while trying to conceive?
Some people continue prescribed ADHD medicine while trying to conceive after an individual review; others reduce, switch or pause treatment. Use the exact active ingredient, dose and formulation, and do not change the plan without the prescriber.
Does ADHD medication affect fertility, ovulation or implantation?
Current human evidence has not established that prescribed dexamfetamine, lisdexamfetamine or methylphenidate causes infertility, stops ovulation, damages egg quality or prevents implantation. Direct fertility studies are limited, so uncertainty should be stated rather than treated as proof of no effect.
What should you do if you get a positive pregnancy test while taking ADHD medicine?
Contact the prescribing clinician promptly with the active ingredient, dose and formulation, then follow the preconception plan until you receive advice. Do not make an unplanned medicine change; seek earlier help if symptoms, side effects or safety risks are significant.
Which ADHD medicines are used in Australia?
Australian Prescriber identifies methylphenidate, dexamfetamine and lisdexamfetamine as the main stimulant options for adults, with atomoxetine among the non-stimulant options. The Australian ADHD guideline emphasises treatment decisions that consider symptoms, everyday functioning, quality of life, adverse effects and individual preferences.
| Active ingredient | Common Australian examples | What fertility evidence can say | Pregnancy-planning point |
|---|---|---|---|
| Dexamfetamine Also called dexamphetamine |
Short-acting tablets | Australian product information states that human fertility data are not available. | Category B3. The current product information is cautious in pregnancy, so the medicine, dose and treatment need require individual review. |
| Lisdexamfetamine | Vyvanse | A dedicated lisdexamfetamine fertility study has not been conducted. | Category B3. Use in pregnancy requires an individual assessment of expected benefit and possible risk. |
| Methylphenidate | Ritalin, Ritalin LA, Concerta and other brands | Australian product information states that human fertility data are unavailable. | Category D after observational evidence identified a possible small fetal cardiac-malformation signal. |
| Non-stimulant medicines | Atomoxetine and selected alternatives | Fertility and pregnancy evidence may still be limited. | Changing to a non-stimulant is not automatically safer; treatment response and the evidence for the alternative still matter. |
Australian pregnancy categories are not a ranking from safest to most dangerous. A category letter does not replace the product information or an individual clinical assessment of the active ingredient, dose, timing and treatment need.
Does dexamphetamine affect fertility?
Current human evidence does not establish that prescribed dexamfetamine causes infertility. Australian product information states simply that human fertility data are unavailable. That means there is no evidence-based basis for saying the medicine definitely reduces fertility, but there is also not enough direct fertility research to promise that it has no effect in every person.
For practical purposes, separate four questions:
- Does dexamphetamine prevent pregnancy? It is not established as a contraceptive.
- Does dexamphetamine stop ovulation? Human evidence has not established that it does.
- Does dexamphetamine damage egg quality? Direct human evidence is insufficient to answer this.
- Does dexamphetamine prevent implantation? Human evidence has not established that it does.
Side effects can still matter to reproductive health. Appetite suppression, marked weight change, poor sleep, changes in blood pressure or pulse, mood symptoms and changes in libido can all be relevant to a preconception review. If cycles change, assess the cycle pattern rather than assuming the prescription is the cause.
If repeated well-timed testing shows no clear LH rise, the no LH surge guide explains missed surges, later ovulation and when a wider fertility assessment may be useful.
What do the newest pregnancy studies add before conception?
Pregnancy studies cannot answer every fertility question, but they matter before conception because exposure can occur before a pregnancy test turns positive. The strongest Australian evidence remains observational, so it can identify associations and treatment patterns but cannot tell one person exactly what will happen.
A 2024 Western Australian cohort compared 547 people who continued dexamphetamine, 297 who ceased during pregnancy and 844 who had used ADHD medicine before pregnancy without dispensing during pregnancy. Continuing dexamphetamine was not associated with a broad increase in severe maternal or neonatal outcomes compared with ceasing, while the non-exposed comparison group had more favourable results for several outcomes. The authors noted important limitations, including exposure timing, confounding and inability to assess spontaneous pregnancy loss fully.
A 2025 Western Australian cohort compared 852 dexamphetamine-exposed pregnancies with 65 methylphenidate-exposed pregnancies. Most measured maternal and neonatal outcomes were comparable, but the methylphenidate group was small, so the study cannot establish that the medicines have identical pregnancy risk.
A 2026 New South Wales linked-data study included 312,697 births. ADHD medicine use during pregnancy was associated with higher rates of gestational hypertension and gestational diabetes compared with matched unexposed pregnancies, but several estimates became smaller when compared with people who had used ADHD medicine before pregnancy. The authors concluded that it remains unclear how much reflects the medicine rather than ADHD or related health factors.
Additional UK and Nordic evidence adds context. UKTIS recommends an individual benefit-risk discussion for therapeutic dexamfetamine and lisdexamfetamine and reports no established increase in major congenital malformations with early therapeutic amphetamine exposure, while evidence for other outcomes remains mixed and confounded. Its methylphenidate review retains the possible cardiac signal and other uncertainties.
Recent Norwegian and Norwegian-Swedish register studies reported associations between ADHD medicine dispensing and miscarriage or preterm birth. These studies are important signals, but prescription records do not prove every dose was taken, and observational research cannot remove all differences in ADHD severity, other medicines and health factors.
When should you review ADHD medication before pregnancy?
Healthdirect recommends seeing a doctor about 3 to 6 months before trying to become pregnant. RANZCOG pre-pregnancy guidance also includes review of pre-existing conditions and medicines before conception. If you are already trying, book the review now rather than waiting for a positive test.
Bring the medicine box, a current medication list or a clear photo of the dispensing label. The appointment should cover the active ingredient, dose, short-acting or long-acting formulation, what happens when a dose is late or missed, appetite, weight, sleep, blood pressure, pulse, mood, driving, work safety, other medicines and any non-prescribed stimulant use.
General preconception care still matters. Review supplements, vaccinations and other medicines as part of the same plan; the guide to prenatal vitamins before pregnancy can help you prepare questions about folic acid, iodine and supplement duplication.
How long should you stop dexamphetamine before trying to get pregnant?
There is no universal evidence-based number of days, weeks or cycles that applies to everyone taking dexamphetamine. Drug clearance is only one part of the decision. The prescriber also needs to consider the dose, formulation, ADHD severity, functional risks, side effects, other medicines and whether a treatment change is actually appropriate before conception.
Australian Prescriber notes that psychostimulants and atomoxetine generally do not require a taper for pharmacological safety. That does not make a sudden self-directed change a good plan. A gradual reduction may lessen lethargy or loss of motivation, and medicine-specific Consumer Medicine Information can give different stopping advice. The practical rule is to plan the change with the prescriber rather than create a DIY washout period.
How do clinicians decide whether to continue, reduce, switch or stop?
The comparison is not medicine risk versus no risk. Reduced treatment can affect concentration, impulsivity, emotional regulation, driving, work, meals, sleep, appointment attendance and mental health. The safest workable plan weighs pregnancy evidence against the consequences of undertreated ADHD.
| Option | When it may be discussed | What still needs a plan |
|---|---|---|
| Continue | Treatment benefit is substantial and adverse effects are controlled. | Monitoring, positive-test action and maternity-team review. |
| Adjust | Benefit remains important but dose timing, appetite, sleep, blood pressure or duration of effect needs attention. | How function changes after adjustment and when to reassess. |
| Switch | Another medicine may offer a better individual balance. | The new medicine’s response, adverse effects and evidence gaps. |
| Supervised pause | Symptoms may remain manageable without medicine for a period. | Relapse signs, unsafe driving or work, mood change and a restart/review threshold. |
Neuroaffirming supports can make an agreed medicine change more manageable. Useful options may include visible routines, reminders, simplified meal planning, appointment notes, workplace adjustments, ADHD-informed psychological support and involving a trusted person in important discussions.
ADHD Preconception Medicine Record
Use this as a discussion record at a GP, prescribing specialist, pharmacist or fertility appointment. It is not a dosing tool.
| Record | What to write down |
|---|---|
| 1. Medicine | Product, active ingredient, formulation, strength, current dose and usual timing. |
| 2. What treatment helps | Driving, work, study, meals, appointments, parenting, emotional regulation, impulsivity or other daily functions. |
| 3. Missed or changed dose effects | What happens to attention, fatigue, mood, sleep, driving, eating or safety when treatment changes. |
| 4. Side effects and monitoring | Appetite, weight, sleep, blood pressure, pulse, anxiety, palpitations, libido or other concerns. |
| 5. Other exposures | Prescription medicines, pharmacy medicines, supplements, caffeine, nicotine, alcohol and non-prescribed substances. |
| 6. Plan while trying | Continue, adjust, switch or supervised pause; monitoring and next review date. |
| 7. Fertility-treatment plan | Instructions for ovulation induction, IUI, IVF, egg collection, embryo transfer and any procedure-day medicine directions. |
| 8. Positive-test plan | Who to contact, what remains unchanged while waiting for advice and what requires earlier review. |
| 9. Care team | Prescriber, GP, pharmacist, fertility clinic and future maternity-care team. |
Can ADHD medicine affect male fertility?
The Australian medicine information for dexamfetamine, lisdexamfetamine and methylphenidate does not provide a reliable human paternal-fertility estimate. That means a delayed pregnancy should not be attributed to a male partner’s ADHD prescription without assessing the usual male-fertility factors.
If conception is taking longer than expected, semen analysis can assess sperm concentration, movement and shape as part of the usual male-fertility work-up. The Fertility Society of Australia and New Zealand describes semen analysis as a core male-fertility test, and Fertility2Family’s male fertility assessment explains what may happen next.
Using ovulation tests and pregnancy tests while taking ADHD medicine
Standard prescribed ADHD medicines do not contain luteinising hormone (LH) or human chorionic gonadotrophin (hCG), the hormones detected by home ovulation and pregnancy tests. Timing, urine concentration, technique, the device instructions and fertility medicines containing hCG are more relevant explanations for confusing results.
Home ovulation tests can help identify the urinary LH rise before likely ovulation. They cannot confirm the exact release of an egg, measure egg quality, diagnose implantation or show whether an ADHD medicine has affected fertility. The fertile window guide explains how an LH result fits with the days when conception is possible.
If you are deciding when pregnancy testing becomes useful, the pregnancy-test accuracy by DPO guide explains why an early negative can change later. If a period remains late and tests stay negative, the late period and negative pregnancy test guide covers common next steps.
What if you are having IVF, IUI or an embryo transfer?
Use the fertility clinic’s medicine and testing plan rather than a general online washout period. Tell the clinic the exact active ingredient, dose and formulation, and make sure the fertility clinician and ADHD prescriber know about any planned change.
The clinic may give specific instructions around ovulation induction, IUI, egg collection, embryo transfer or another procedure. Do not skip ADHD medicine only on retrieval, transfer or “two-week wait” days unless that has been agreed. The useful question is what the clinic and prescriber want you to do for that exact treatment cycle.
If treatment has not started or conception is taking longer than expected, the guide to when to see a fertility specialist explains the Australian referral pathway. Take the medicine record above so the fertility team can see the treatment benefits, side effects and positive-test plan in one place.
What should you do after a positive pregnancy test?
Contact the prescribing clinician promptly and provide the active ingredient, dose, formulation, last dose and any other medicines or supplements. Follow the plan agreed before conception if you have one.
Do not assume treatment must stop that day, and do not assume it should continue unchanged until the next routine appointment. The clinician may keep treatment stable, adjust it, arrange monitoring or involve the maternity-care team. Fertility2Family’s positive pregnancy test next-steps guide covers the wider Australian early-pregnancy pathway.
When should you seek prompt or urgent help?
Contact the prescriber sooner if a medicine change causes a marked loss of function, unsafe driving or work risk, severe mood change, major sleep disruption, ongoing weight loss, persistent palpitations or other symptoms that concern you.
Call triple zero on 000 for a life-threatening emergency, such as collapse, a seizure, severe breathing difficulty or immediate risk of serious harm. Australian medicine information also lists potentially serious cardiovascular and psychiatric adverse effects that warrant medical assessment.
Frequently Asked Questions about ADHD medication and fertility in Australia
Can dexamphetamine affect egg quality?
Human evidence has not established that prescribed dexamfetamine damages egg quality, and Australian product information states that human fertility data are unavailable. If conception is delayed, assess ovulation, age, reproductive history and other fertility factors rather than assuming the medicine is the cause.
Can Vyvanse affect ovulation or conception?
A dedicated human fertility study of lisdexamfetamine has not been conducted. Current evidence does not establish that Vyvanse prevents ovulation or conception, but its pregnancy information and your functional response still need review before treatment is changed.
Does Ritalin or Concerta affect fertility?
Human fertility data for methylphenidate are unavailable. Its pregnancy information differs from dexamfetamine and lisdexamfetamine because Australian regulators identify a possible small fetal cardiac-malformation signal, so Ritalin or Concerta needs a medicine-specific preconception review.
Can ADHD medication make periods irregular?
Irregular periods are not a proven direct effect of every ADHD medicine. Appetite loss, marked weight change, sleep disruption, stress, another medicine and unrelated hormonal conditions can alter cycles, so persistent changes should be assessed rather than automatically attributed to ADHD treatment.
Is a low dose automatically safer while trying to conceive?
No dose can be declared universally safe from the number alone. The active ingredient, formulation, frequency, treatment benefit, side effects, other medicines and pregnancy plan all matter, so do not continue, reduce or stop solely because a dose sounds low.
Are non-stimulant ADHD medicines automatically safer before pregnancy?
No. Non-stimulant medicines have their own evidence limits, adverse effects and treatment considerations. Switching can reduce symptom control or introduce a different uncertainty, so a change should be based on the individual clinical plan rather than the stimulant versus non-stimulant label.
Next Steps in Australia
- Book the preconception review. Bring the dispensing label, current medicine list and the completed medicine record.
- Agree on one written plan. Cover trying to conceive, fertility treatment, a positive pregnancy test and what to do if symptoms or side effects change.
- Use home tests for the job they can do. LH tests help with fertile-window timing and hCG tests help detect pregnancy; neither measures medication safety.
- Escalate appropriately. If cycles stay unclear, side effects are significant or conception is taking longer than expected, move from home tracking to a GP, prescribing clinician or fertility service.
Last reviewed: 3 September 2026
Next scheduled review: September 2027
References
Fertility2Family articles are researched using Australian Government health guidance, professional clinical recommendations and peer-reviewed medical literature. The references below were used to research and medically review this article and provide additional reading for readers who want to explore the evidence in more detail.
Australian Prescriber. Pharmacological management of attention deficit hyperactivity disorder in adults
Australian clinical review of adult ADHD medicines, monitoring, discontinuation principles and patient-centred treatment decisions, including dexamfetamine, lisdexamfetamine, methylphenidate and atomoxetine.
Australasian ADHD Professionals Association. Australian Evidence-Based Clinical Practice Guideline for ADHD
NHMRC-approved Australian ADHD guideline integrating evidence, multidisciplinary clinical expertise and lived experience, with treatment decisions focused on symptoms, everyday functioning, quality of life and individual preferences.
RANZCOG. Pre-pregnancy counselling (C-Obs 3a) Clinical Guideline
Version 13.1 Australian and New Zealand pre-pregnancy guideline covering medical conditions, medication review, ovulation detection, supplements, mental health and preparation before conception.
Centre of Perinatal Excellence. ADHD in pregnancy
Australian perinatal ADHD guidance describing neuroaffirming support, functional challenges, medication discussions and the importance of individual planning rather than unsupported or abrupt treatment decisions.
Therapeutic Goods Administration. Australian categorisation system for prescribing medicines in pregnancy
TGA guidance explaining that Australian pregnancy categories are not a safety ranking and that medicine decisions require interpretation of the full evidence, dose, timing and clinical circumstances.
Therapeutic Goods Administration. Methylphenidate – use in pregnancy
Australian safety update explaining methylphenidate’s change from pregnancy category B3 to D after observational evidence identified a possible small increase in fetal cardiac malformations.
Australian Commission on Safety and Quality in Health Care. Aspen Dexamfetamine
Current Australian dexamfetamine Consumer Medicine Information and Product Information covering the active ingredient, monitoring, pregnancy category B3 and the absence of available human fertility data.
Australian Commission on Safety and Quality in Health Care. Vyvanse
Current Australian lisdexamfetamine medicine information covering active ingredient, adverse effects, pregnancy category B3, benefit-risk review and the absence of a dedicated lisdexamfetamine fertility study.
Australian Commission on Safety and Quality in Health Care. Ritalin
Current Australian methylphenidate medicine information covering human fertility-data limitations, pregnancy category D, the possible cardiac-malformation signal and individual benefit-risk assessment.
Healthdirect Australia. Planning for your pregnancy
Australian preconception guidance recommending medical review before trying to conceive, including medicines, health conditions, supplements, ovulation tracking and when fertility assessment may be appropriate.
Archives of Women’s Mental Health. Investigating maternal and neonatal health outcomes associated with continuing or ceasing dexamphetamine treatment for women with attention-deficit hyperactivity disorder during pregnancy: a retrospective cohort study
Western Australian cohort comparing dexamphetamine continuation, cessation during pregnancy and pre-pregnancy exposure, with important limitations around confounding, exposure timing and early pregnancy-loss ascertainment.
Neurodiversity. Maternal and Neonatal Outcomes Associated with the use of Dexamphetamine or Methylphenidate in Pregnancy: A Retrospective Cohort Study
Western Australian cohort comparing 852 dexamphetamine-exposed and 65 methylphenidate-exposed pregnancies, reporting broadly comparable measured outcomes while emphasising the small methylphenidate group and need for larger studies.
Archives of Women’s Mental Health. Attention-deficit/hyperactivity disorder medication use and cardiometabolic conditions in pregnancy: a population-based cohort study
New South Wales linked-data cohort examining gestational hypertension, pre-eclampsia and gestational diabetes, while showing uncertainty about medication effects versus underlying ADHD and related factors.
UK Teratology Information Service. Use of therapeutic amfetamines in pregnancy
UK specialist evidence review for therapeutic dexamfetamine and lisdexamfetamine exposure, summarising congenital-malformation, preterm-birth and other pregnancy data and recommending individualised benefit-risk assessment.
UK Teratology Information Service. Use of methylphenidate in pregnancy
UK specialist evidence review of methylphenidate in pregnancy, including overall malformation data, a possible cardiac signal, miscarriage findings and the risks of destabilising effective treatment.
British Journal of Psychiatry. Attention-deficit hyperactivity disorder medication use in pregnancy and risk of miscarriage
Norwegian register-based case-control study examining filled ADHD medicine prescriptions and miscarriage among pregnancies affected by ADHD, with exposure, confounding and dispensing-versus-use limitations.
Paediatric and Perinatal Epidemiology. Attention-Deficit/Hyperactivity Disorder Medication Use in Pregnancy and Risk of Preterm Birth: A Population-Based Cohort Study
Norwegian and Swedish population cohort examining ADHD medicine exposure timing and duration in relation to preterm birth, with modest associations that remain observational rather than individually causal.
Fertility Society of Australia and New Zealand. Male Infertility
Australian fertility information describing male-factor causes and the role of GP or specialist assessment, including semen analysis of sperm count, motility and morphology when fertility concerns persist.
Pregnancy, Birth and Baby. Ovulation and fertility
Australian guidance on ovulation, the fertile window and urinary LH testing, including what a positive ovulation predictor result can suggest and what home testing cannot confirm.
Pregnancy, Birth and Baby. Pregnancy tests
Australian guidance on urine pregnancy tests, hCG detection, test timing, urine concentration, following device instructions, early false negatives and seeking care after a positive result.